['sickle cell disease']
['alemtuzumab', 'cyclophosphamide', 'sirolimus']

        Patient Eligibility:

          -  Patients with sickle cell disease are eligible if they have any of the following
             complications:

               -  Stroke or central nervous system event lasting longer than 24 hours

               -  Frequent vaso-occlusive pain episodes, defined as ≥ 3 per year requiring
                  emergency room, acute care center, or hospital admissions.

               -  Recurrent episodes of priapism, defined as ≥ 2 per year requiring emergency room
                  visits

               -  Acute chest syndrome with recurrent hospitalizations, defined as ≥ 2 lifetime
                  events

               -  Red-cell alloimmunization (≥ 2 antibodies) during long-term transfusion therapy

               -  Bilateral proliferative retinopathy with major visual impairment in at least one
                  eye

               -  Osteonecrosis of 2 or more joints

               -  Sickle cell nephropathy, defined by a GFR < 90mL/min/1.73m2 or the presence of
                  macroalbuminuria (urine albumin > 300 mg/g creatinine)

               -  Pulmonary hypertension, defined by a mean pulmonary artery pressure > 25mmHg

          -  Age 16-60 years

          -  Karnofsky performance status of 60 or higher

          -  Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40%

          -  Adequate pulmonary function, defined as diffusion lung capacity of carbon monoxide ≥
             50% predicted (after adjustment for hemoglobin concentration)

          -  Estimated GFR ≥ 50mL/min as calculated by the modified MDRD equation

          -  ALT ≤ 3x upper limit of normal

          -  HIV-negative

          -  Patient is pregnant

          -  Patient is able and willing to sign informed consent

          -  Patient has an HLA-haploidentical relative
      